Navigation Links
ALS TDI Tri-State Trek Charity Bike Ride to Take Place July 19-21
Date:6/17/2013

CAMBRIDGE, Mass., June 17, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) will hold its 11th annual Tri-State Trek charity cycling event on July 19-21, 2013. The Tri-State Trek is a three-day, 270 mile bike ride from Newton, MA to Greenwich, CT with the mission to end amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

(Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)

Beginning in Newton, MA, the Tri-State Trek passes through 46 communities and includes 12 rest stops, two lunch stops and two overnight stays. Cyclists can ride all or part of the route; all three days, one of the three days, or a two-day combination. In addition, volunteers and crew are needed and encouraged to participate throughout the three days.

Since 2003, the Trek has grown from 16 cyclists to more than 400 participants in 2012. The event has raised more than $3 million for ALS TDI, a nonprofit biotechnology institute in Cambridge, MA dedicated to develop effective treatments and a cure as soon as possible for patients today. Fundraising efforts for ALS TDI have helped the organization test more potential treatments for ALS than any other research lab in the world, one of which is being explored through a research agreement with Biogen Idec and UCB, and a second called, TDI-132/Gilenya®, which is being investigated through a Phase II clinical trial.

"The Tri-State Trek is one way we gather with the ALS community to share in a physically challenging event to recognize a disease that is so much worse," says Steve Perrin, Ph.D., CEO and Chief Scientific Officer of ALS TDI and a cyclist in the Tri-State Trek. "Through funding from the event, our scientists are able to continue making discoveries with the aim of developing effective treatments and a cure for Lou Gehrig's disease."

For more information on riding, volunteering, donating or coming out to cheer, call 617-441-7200 or visit www.TriStateTrek.com.

About ALS 
Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) is a progressive neurodegenerative disease that leads to paralysis, due to the death of motor neurons in the spinal cord and brain. There is no known cure for the disease. About 5,000 people in the U.S. are diagnosed with ALS each year; the incidence is similar to multiple sclerosis. However, with no effective treatment, the average patient survives only two to five years following diagnosis. There are about 30,000 people in the U.S. diagnosed with ALS today. The worldwide population of ALS patients is estimated at 450,000.

About ALS Therapy Development Institute (ALS TDI)
The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) as soon as possible for patients today. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust target discovery program, while simultaneously operating the world's largest efforts to preclinically determine the efficacy of potential therapeutics; including a pipeline of dozens of small molecules, protein biologics, gene therapies and cell-based constructs. The world's first nonprofit biotech institute, ALS TDI employs 30 professional scientists and evaluates dozens of potential therapeutics each year and is currently executing a Phase IIA clinical trial of TDI-132 (Novartis' Gilenya®) in ALS patients.  Built by and for patients, the Cambridge, Massachusetts based research institute collaborates with leaders in both academia and industry to accelerate ALS therapeutic development, including Biogen Idec, UCB, the Gladstone Institutes, MDA and RGK Foundation. For more information, please visit us online at www.als.net.

Media Contact:
Mari Sullivan, Public Relations Manager, ALS TDI, 617-441-7220, msullivan@als.net


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
2. LinkTech Inc. Launches Ideal Replacement for a Luer Fitting
3. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
4. 1DegreeBio Inc. Boosts Review-Driven Reagent Marketplace with New e-Commerce Platform
5. Z Trim Helps Food Manufacturers "Clean" Their Labels - Replace Chemically Modified Foods With "Corn Fiber"
6. Utah, There is No Better Place U.S. Chamber of Commerce Ranks Utah as the Top Performer in the Nation
7. Safe Non-Toxic Enzyme Cleaner Replaces Bleach as Leading Mold & Flood Cleaning Solution
8. Future of Pre- and Probiotics to be Discussed by Kibow Biotech Founder During SupplySide MarketPlace 2013 Global Expo & Conference
9. Mother’s Workplace Exposures During Pregnancy Cause Risk of Cleft Lip in Children
10. Comark Explodes into the HAZLOC Marketplace by Unveiling New CID2 Workstation at the Offshore Technology Conference 2013
11. A Homegrown Smile? Atlanta Dentist Examines New Research on the Biological Teeth Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... 10, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer Jaye ... GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to achieving ...
Breaking Biology Technology:
(Date:8/15/2017)... Va. , Aug. 15 2017   ivWatch LLC , ... of intravenous (IV) therapy, today announced receipt of its ISO 13485 ... developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the ... "This is ...
(Date:5/23/2017)... first robotic gym for the rehabilitation and functional motor sense evaluation of ... Italy . The first 30 robots will be available from June ... . The technology was developed and patented at the IIT laboratories and ... thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):